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Gastroesophageal reflux disease (GERD) is a disease with serious
consequences that may result in significant impairment in quality
of life and disease morbidity. Across all grades of severity of symp-
toms and severity of underlying esophageal disease, proton pump
inhibitors (PPIs) provide therapeutic gains over prokinetics (PKs)
or H2 receptor antagonists (H2RAs). The potential cost effective-
ness of using medications with higher acquisition costs that may
lower health care costs overall is often disregarded when conduct-
ing cost comparisons with medications having lower ‘up-front’
costs. Limiting therapy to less effective agents condemns many pa-
tients to protracted suffering, repeated physician visits and need-
less reinvestigation of symptoms that could have been resolved by
appropriate initial therapy. Based on current data, use of any clas-
sification of symptom severity as a basis for selecting one class of
therapeutic agents over another for first line therapy (ie PKs,
H2RAs for ‘mild’ GERD, versus a PPI for ‘severe’ disease) is unwar-
ranted.
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Deuxième consensus canadien sur le reflux
gastro-œsophagien : de nouveaux concepts en
vue
RÉSUMÉ : Le reflux gastro-œsophagien est une maladie qui a des
conséquences graves et qui peut entraîner une atteinte de la
qualité de vie et une morbidité significatives. Peu importe
l’intensité des symptômes et le degré d’atteinte œsophagienne, les
inhibiteurs de la pompe à protons (IPP) offrent des avantages
thérapeutiques supérieurs à ceux des procinétiques ou des anti-H
2
.
Le rapport coût-efficacité potentiel des médicaments plus coûteux
qui peuvent faire baisser les dépenses globales en soins de santé est
souvent négligé lorsque l’on procède à des comparaisons de coûts
sur des médicaments avec pour objectif de toujours obtenir le prix
direct le plus bas. En limitant le traitement à des agents moins
efficaces, on condamne de nombreux patients à une souffrance
inévitable, à des visites répétées chez le médecin et à des examens
superflus pour des symptômes qui auraient pu être soulagés dès le
départ avec un traitement adéquat. Sur la base des données
actuelles, l’emploi d’une classification des symptômes selon leur
gravité pour choisir une classe d’agents thérapeutiques par rapport
à une autre en traitement de première intention (p. ex.,
procinétique, anti-H
2
pour le RGO bénin vs IPP pour une maladie
grave) n’est pas justifié.
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The publication of the Second Canadian Gastroesophag-eal Reflux Disease Consensus Conference on the man-
agement of patients with gastroesophageal reflux disease
(GERD) (1) was awaited with considerable interest and ex-
pectation. Publication of the document took place 15
months after the conference in June 1996, reflecting the
time needed to write and revise the manuscript to incorpo-
rate revisions requested by the 38 participants who attended
the conference. The many controversies involved, particu-
larly regarding the step-up versus the step-down approach to
therapy, lengthened the publication process. Moreover, be-
cause of the lack of previously approved rules of revision, re-
visions in the cognitive aspects of the document were
necessary in order to incorporate more recently available lit-
erature. Consensus signifies agreement, and the nature of the
controversy surrounding the development of a treatment al-
gorithm, and the immense commercial implications in-
volved, implied the need to reduce the protocol to the lowest
common denominator of physician comfort rather than as-
piring to the heights of idealism for the best approach based
on evidence and common sense.
This paper examines new evidence, reassesses old data
and interprets possible choices for treatment of patients with
GERD, all of which form the basis for the proposal that step-
down therapy is the only treatment for patients with GERD
that can be supported by the evidence. Step-down therapy
denotes a short two- to four-week course of therapy with a
proton pump inhibitor (PPI), after which the patient is reas-
sessed. At the time of reassessment the physician may initi-
ate a step-down to a lower dose or intermittent PPI therapy,
‘less potent’ H2 receptor antagonist (H2RA) therapy or
prokinetic (PK) therapy. Endoscopy is not necessary to diag-
nose GERD and is indicated only if the patient has alarm
symptoms, or if reflux symptoms persist or recur despite ade-
quate therapy. Patients who require long term maintenance
therapy should undergo an elective, ‘once-in-a-lifetime’ en-
doscopy to screen for Barrett’s esophagus, provided that they
are eligible for, and desirous of, appropriate therapy if Bar-
rett’s esophagus is diagnosed.
LIMITED USE OF A SYMPTOM SEVERITY SCALE
Table 4 in the introductory article of the consensus docu-
ment outlines an arbitrary clinical scale estimating the symp-
tom severity of GERD (1). Although it is a plausible scale,
no data exist to substantiate the classification of symptoms as
‘mild’ if they have been present for less than six months, if
they occur less than three times per week or if the patient
rates symptom intensity as ‘three or less’ on an undefined
scale of 10. It is well documented that the symptoms of acid
reflux disease are not reliable predictors of the presence or se-
verity of underlying esophagitis. Mild symptoms may mask
the presence of severe esophagitis (2-5). For example, ap-
proximately 80% of patients classified as having mild symp-
toms of acid reflux disease had underlying esophagitis grades
two to four, and nearly 40% had esophagitis grades three and
four (Figure 1). Furthermore, a recent meta-analysis of
pooled data from 16 independent clinical trials that studied a
total of 3478 patients with acid reflux disease demonstrated
that approximately 70% of patients experienced moderate to
severe heartburn, irrespective of the severity of the underly-
ing esophagitis (6). Thus, patients with mild symptoms may
have severe erosive esophagitis, and patients who do not
have erosive esophagitis may experience severe symptoms.
Furthermore, ‘mild’ symptoms, or a diagnosis of ‘mild’ esoph-
agitis, are not a guarantee of a good response to ‘mild’ or less
potent therapy. Even for patients with grade II erosive
esophagitis, the group that comprises approximately 62% of
patients studied in clinical trials (7), there is a major thera-
peutic gain using PPIs over H2RAs; the rate of healing and
symptom relief is approximately twice as fast (7).
The symptom severity scale was introduced partly be-
cause it was recognized that primary care physicians base pa-
tient management largely on symptoms. However, to be
useful in practice a symptom scale should first be validated to
ensure that it can provide a predictable basis for determining
appropriate investigation and treatment strategies. Because
the symptom scale proposed by the consensus guidelines has
not been validated, a number of practical management prob-
lems are created:
 Very mild symptoms may require little, if any, therapy,
but there are no data to indicate an appropriate
threshold for initiating therapy.
 The presence of ‘mild’ symptoms may mask severe
mucosal damage that will not respond to treatment with
lifestyle modifications or H2RAs.
 There are no data to indicate that PPI therapy is
medically inappropriate for some patients with ‘mild’
symptoms.
 The duration of symptoms for more than six months has
no bearing on symptom severity; it is simply indicative
of chronicity.
 Limiting the initial use of PPIs deprives physicians of a
potentially cost effective diagnostic tool. In the patient
who has typical symptoms, a good symptomatic response
to a short course of PPI therapy is virtually diagnostic of
reflux disease. Provided that the patient’s response to
therapy is assessed within two weeks, a step-down
approach need not be more costly.
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Figure 1) Esophagitis by endoscopic grade in patients with mild symp-
toms of acid reflux disease. Data from references 3,4
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In conclusion, current data do not warrant use of any clas-
sification of symptom severity as a basis for selecting one
class of therapeutic agents over another for first line therapy
(ie, PK or H2RA for ‘mild’ GERD, versus PPI for ‘severe
disease’).
MILD THERAPY IS LIMITED FOR MILD
SYMPTOMS OR MILD ESOPHAGITIS
Some physicians are uncomfortable prescribing ‘potent’
PPI therapy to relieve symptoms arising from a condition
that they consider to be relatively trivial; however, GERD is
not a trivial condition. Using either the Psychological Gen-
eral Well-Being (PGWB) index or the Gastrointestinal
Symptomatic Rating Scale (GSRS), it is clear that reflux
symptoms, with or without associated esophagitis, signifi-
cantly impair quality of life (8-11). Accepting that there is a
dissociation between the severity of symptoms and the se-
verity of underlying esophageal disease, employing a step-up
approach to therapy withholds effective PPI therapy from
patients who require effective acid inhibition. Furthermore,
PPIs are superior to PKs and H2RAs for treating mild symp-
toms arising in patients with endoscopy-negative reflux dis-
ease (ENRD) and across all grades of erosive esophagitis. In
five large, double-blind trials including over 2500 patients
with GERD, with or without associated esophagitis, omepra-
zole provided better symptom relief than ranitidine 150 mg
bid or cisapride 10 mg qid (12-16). The therapeutic gains at
four weeks with omeprazole 20 mg administered once daily
were 21% over ranitidine (P<0.0001) and 26% over cisa-
pride (P<0.01); omeprazole 10 mg daily produced therapeu-
tic gains of 9% and 13%, respectively (Figure 2). Differences
were also noted between PPI and PK (16). Omeprazole also
produced therapeutic gains of 28% to 30% over placebo in
the four-week resolution of heartburn (12,13,15). Rapid
symptom relief was achieved in primary care patients who
had heartburn, with or without esophagitis (16). Regurgita-
tion was also decreased, and quality of life (PGWB scale)
was normalized (9,11). PPIs consistently produced higher
healing rates than H2RAs in patients with erosive esophagi-
tis, irrespective of the severity of the esophagitis (2), and
without the development of tolerance that occurs with
H2RA (17-20).
It is noteworthy that much of the controversy about
choice of therapy is related to the ‘up-front’ (acquisition)
cost of therapy. PPIs are used less often not because they are
too ‘potent’, but because they are relatively costly. If PPIs
and H2RAs were equal in price, little, if any, controversy
regarding step-up versus step-down therapy would exist;
however, most cost comparisons consider only ‘up-front’
drug acquisition costs. The Canadian Coordinating Office
for Health Technology Assessment health economic analy-
sis indicates that using more costly medications may reduce
overall health care costs provided that they are more effec-
tive. Thus, because of the rapid and high rate of symptom
resolution achieved with PPIs and the higher probability of
complete healing of associated esophagitis, the patient with
GERD can be managed more effectively, whether the end-
point is resolution of symptoms, improved quality of life or
healing of esophagitis. Limiting therapy to less effective
agents condemns many patients to protracted suffering, re-
peated physician visits and needless reinvestigation of symp-
toms that could have been relieved by appropriate initial
therapy.
LIMITED USE OF PKS AND H2RAs
FOR MAINTENANCE THERAPY
The healing of erosive esophagitis and resolution of reflux
symptoms are a temporary respite for nearly two-thirds of
patients with GERD. Despite effective acute therapy, symp-
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Figure 3) Predictable maintenance treatment with omeprazole in reflux
esophagitis, irrespective of pre-entry grade
Figure 2) Resolution of heartburn in patients with symptomatic acid
reflux disease. Data from references 12-16
Figure 4) Omeprazole is superior to ranitidine and cisapride in maintain-
ing pateints with healed reflux esopagitis in long term endoscopic remission
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toms and esophageal erosion recur in the majority of patients
with reflux esophagitis and, in studies of patients with ero-
sive esophagitis, relapse rates of 80% to 90% have been
documented within six to 12 months of stopping therapy
(21). Thus, maintenance therapy is indicated for a substan-
tial proportion of patients who initially require acute medi-
cal therapy. The Second GERD Consensus Conference,
therefore, recommended that these patients be maintained
on the agent that had been successfully used to treat their re-
flux symptoms and/or erosive esophagitis. However, regard-
less of which therapeutic agent was used initially and of
the severity of the reflux esophagitis, PPIs produce higher
symptomatic and endoscopic remission rates than do H2RAs
or PKs (Figures 3,4). Although H2RAs are effective for some
patients with mild GERD, they are of questionable efficacy
in patients with more severe erosive esophagitis (Savary-
Miller grades two to four) (21).
For patients with erosive esophagitis, PPIs clearly provide
a superior outcome in terms of symptom relief and freedom
from recurrent esophageal injury. However, particularly in
the primary care setting, it is impractical to arrange for endo-
scopy in all patients with reflux symptoms, either at initial
presentation or after therapy. Thus, in most instances physi-
cians must rely on symptoms to gauge disease severity and
treatment success. The relevance of studies conducted in
patients with erosive esophagitis in primary care practice
remains controversial, but recent studies suggest that 29% to
51% of reflux patients have erosive esophagitis (14,22-24).
Patients with endoscopy-positive reflux disease are indistin-
guishable, with respect to symptom severity, from patients
with ENRD (6). These observations, combined with studies
showing that PPIs provide better symptom relief than PKS or
H2RAs in patients with ENRD (14,16), strongly suggest that
PPIs are superior for maintenance therapy over the full
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Figure 5) Suggested approach to patients with typical gastroesophageal reflux disease (GERD) symptoms. OTC-H2RA Over-the-counter histamine H2
receptor antagonists; pH Ambulatory esophageal pH monitoring; PPI Proton pumb inhibitor; Rx Reaction
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spectrum of GERD. It is also irrelevant whether some
GERD patients develop recurrent symptoms in the absence
of erosive esophagitis. Symptomatic ENRD is a chronic con-
dition (10,25); about half of these patients experience recur-
rent symptoms within six months of stopping prescription
therapy, despite the use of antacids. Using short courses of
PPIs to treat symptomatic recurrences is sensible, given
their superior pain relief compared with PKs or H2RAs
(7,14,16).
Is there any risk that intermittent use of PPIs for recurrent
symptoms increases the risk of the patient developing a com-
plication? Follow-up of patients who initially had mild
esophagitis showed that more severe esophagitis later oc-
curred in 20% of these patients (26). There is no evidence
that intermittent PPI therapy reduces this risk, but there is
also no evidence that it increases the risk of progression. Fur-
thermore, because PPIs provide a greater likelihood of heal-
ing recurrent esophagitis, independent of an overall increase
in the propensity for severe esophagitis, it is more likely that
the risk of esophageal ulceration or stricture will be de-
creased (27).
FOR CONSIDERATION
Optimal therapy for patients with GERD eliminates re-
flux symptoms and prevents the development of complica-
tions. The symptom pattern correctly predicts the diagnosis
of GERD in at least two out of three patients (28), and self
administered questionnaires may also facilitate the diagnosis
of GERD (6,31). Many patients with GERD experience
symptoms that are sufficiently severe to impair their quality
of life (29,30). The endoscopic severity of esophagitis corre-
lates poorly with GERD symptom severity (31). In the ab-
sence of alarm symptoms, upper gastrointestinal series or
endoscopy are not indicated (32). It is controversial whether
endoscopy is indicated for patients with nonresponsive re-
flux symptoms, and 24 h esophageal pH monitoring may be
required in patients with reflux symptoms that persist after
administration of standard doses of a PPI to determine
whether higher or more frequent doses are needed. If neither
erosive disease nor Barrett’s esophagus is found on initial en-
doscopy, further endoscopies are not indicated, even in the
presence of continued symptoms.
Treatment with a PPI may be used effectively as a diag-
nostic therapeutic trial in patients with troublesome, but not
alarm, symptoms of GERD (33-35). Health-related quality
of life in patients with GERD is more likely to be restored by
initial treatment with a PPI than with an H2RA
(9,10,15,36,37). The debate continues as to whether step-up
therapy is the preferred strategy or whether PPIs should be
considered the only appropriate therapy for symptoms of
GERD. Antacids, alginates, over-the-counter H2RAs and
lifestyle changes are appropriate therapy for trivial or infre-
quent heartburn or regurgitation. However, most patients
have self-medicated by the time they consult a physician.
Recommending step-up therapy is not warranted when the
consequences of ineffective or less effective treatment in-
clude persistent symptoms, impaired quality of life, time lost
from work and repeated physician visits. Thus, the step-up
approach is difficult to support because it delays the institu-
tion of adequate therapy. Inadequate therapy ultimately
leads to more health care dollars being spent on repeated
physician visits, specialist consultations and investigations,
only to culminate in prescribing a PPI that could have initi-
ated therapy in a step-down approach.
Thus, step-up therapy is impractical and inadequate for
many patients. Step-down therapy is only limited in that
some patients may be adequately managed with less potent,
or initially less costly, therapy; however, three-quarters of
patients treated by the step-up approach suffer the conse-
quences of suboptimal therapy. The cost of PPIs is greater
than that of generic H2RAs. The economic argument,
which is based on drug acquisition costs, is often used to sup-
port the step-up approach: use cheaper therapy in all patients
with the hope that endoscopy, complications, poor quality of
life and the later need for a PPI can be avoided. However,
less potent therapy is not necessarily less costly. Acquisition
costs for PKs are almost comparable with those for PPIs, and,
there is, therefore, little support for endorsing the recom-
mendation of the Second GERD Consensus Conference
that PKs be considered as first-line therapy. PK therapy
should be considered not because it is less potent, but be-
cause there are accompanying indicators of altered gastroin-
testinal motility that may respond appropriately to this class
of medication.
The cost of caring for patients with GERD goes far beyond
the cost of the initial physician consultation and the initial
prescription cost. Failure of therapy may lead to follow-up vis-
its, referral and investigations, all of which are costly. Most
patients, if they were properly and honestly informed, would
not tolerate enduring unpleasant, suboptimal symptom re-
lief because funding agencies only support the use of less
effective therapies based on lower initial, up-front drug
acquisition costs. Properly designed clinical trials with
prospective evaluation of the downstream health care costs
are urgently required to settle these important issues.
More debate about better strategies of management,
more studies and more patient-oriented discussions are re-
quired. A simple approach to the patient with GERD
symptoms is proposed to initiate the process of further dis-
cussion (Figure 5). Let’s hear from you – what is your view-
point?
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